A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis.

[1]  U. Capitanio,et al.  Collaborative Review: Factors Influencing Treatment Decisions for Patients with a Localized Solid Renal Mass. , 2021, European urology.

[2]  U. Capitanio,et al.  Hypertension and Cardiovascular Morbidity Following Surgery for Kidney Cancer. , 2020, European urology oncology.

[3]  S. Jackman,et al.  Utilization and operative influence of Renal Mass Biopsy in the Small Renal Mass: Analysis from the CROES Small Renal Mass registry. , 2020, Journal of endourology.

[4]  J. Cheville,et al.  Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. , 2019, European urology.

[5]  Paras H Shah,et al.  Association of Partial versus Radical Nephrectomy with Subsequent Hypertension Risk Following Renal Tumor Resection. , 2019, The Journal of urology.

[6]  M. Brock,et al.  Interdisciplinary comparison of PADUA and RENAL scoring systems for prediction of conversion to nephrectomy in patients with renal mass scheduled for nephron-sparing surgery. , 2019, The Journal of urology.

[7]  J. Cheville,et al.  Predicting Renal Function Outcomes After Partial and Radical Nephrectomy. , 2019, European urology.

[8]  Masami Watanabe,et al.  The 3-D Volumetric Measurement Including Resected Specimen for Predicting Renal Function AfterRobot-assisted Partial Nephrectomy. , 2019, Urology.

[9]  J. Kaouk,et al.  Development and Internal Validation of a Nomogram for Predicting Renal Function after Partial Nephrectomy. , 2019, European urology oncology.

[10]  National Health Commission of PRC.  Chinese guidelines for diagnosis and treatment of renal cell carcinoma 2018 (English version) , 2019, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[11]  J. Cheville,et al.  Radical Versus Partial Nephrectomy for cT1 Renal Cell Carcinoma. , 2018, European urology.

[12]  Paras H Shah,et al.  The Temporal Association of Robotic Surgical Diffusion with Overtreatment of the Small Renal Mass , 2018, The Journal of urology.

[13]  S. Boorjian,et al.  Staging the Host: Personalizing Risk Assessment for Radical Cystectomy Patients. , 2018, European urology oncology.

[14]  U. Capitanio,et al.  Role of Active Surveillance for Localized Small Renal Masses. , 2018, European urology oncology.

[15]  S. Psutka,et al.  Nutritional Predictors of Perioperative Complications and Mortality Following Nephrectomy for Renal Malignancies: A Population-Based Analysis , 2018, Kidney Cancer.

[16]  T. Garg,et al.  Burden of Multiple Chronic Conditions among Patients with Urological Cancer , 2018, The Journal of urology.

[17]  K. Ogan,et al.  Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology , 2017, CA: a cancer journal for clinicians.

[18]  Jeffrey A. Cadeddu,et al.  Adult Urology Oncology : Adrenal / Renal / Upper Tract / Bladder lized Renal Cancer : AUA Guideline , 2017 .

[19]  B. Lane,et al.  Collaborative Review of Risk Benefit Trade-offs Between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses. , 2017, European urology.

[20]  P. Dasgupta,et al.  PADUA and R.E.N.A.L. nephrometry scores correlate with perioperative outcomes of robot‐assisted partial nephrectomy: analysis of the Vattikuti Global Quality Initiative in Robotic Urologic Surgery (GQI‐RUS) database , 2017, BJU international.

[21]  Mark W. Ball,et al.  Partial vs Radical Nephrectomy for T1-T2 Renal Masses in the Elderly: Comparison of Complications, Renal Function, and Oncologic Outcomes. , 2017, Urology.

[22]  U. Capitanio,et al.  Population‐based assessment of cancer‐specific mortality after local tumour ablation or observation for kidney cancer: a competing risks analysis , 2016, BJU international.

[23]  J. Speakman,et al.  Renal cell carcinoma survival and body mass index: a dose–response meta-analysis reveals another potential paradox within a paradox , 2016, International Journal of Obesity.

[24]  E. Bass,et al.  Management of Renal Masses and Localized Renal Cancer: Systematic Review and Meta-Analysis. , 2016, The Journal of urology.

[25]  Mark W. Ball,et al.  Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. , 2015, European urology.

[26]  V. Master,et al.  R.E.N.A.L. (Radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior, and location relative to polar lines) nephrometry score predicts early tumor recurrence and complications after percutaneous ablative therapies for renal cell carcinoma: a 5-year experience. , 2015, Journal of vascular and interventional radiology : JVIR.

[27]  J. Cheville,et al.  Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. , 2015, European urology.

[28]  Mark W. Ball,et al.  Comorbidities and causes of death in the management of localized T1a kidney cancer , 2014, International journal of urology : official journal of the Japanese Urological Association.

[29]  P. Rhee,et al.  Frailty in surgery , 2014, The journal of trauma and acute care surgery.

[30]  C. Ko,et al.  Development and evaluation of the universal ACS NSQIP surgical risk calculator: a decision aid and informed consent tool for patients and surgeons. , 2013, Journal of the American College of Surgeons.

[31]  K. Ogan,et al.  Too frail for surgery? Initial results of a large multidisciplinary prospective study examining preoperative variables predictive of poor surgical outcomes. , 2013, Journal of the American College of Surgeons.

[32]  R. Thompson,et al.  Percutaneous renal cryoablation in obese and morbidly obese patients. , 2013, Urology.

[33]  F. Montorsi,et al.  Comparison of partial vs radical nephrectomy with regard to other‐cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities , 2013, BJU international.

[34]  R. Uzzo,et al.  Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model. , 2012, The Journal of urology.

[35]  M. Menon,et al.  A stage-for-stage and grade-for-grade analysis of cancer-specific mortality rates in renal cell carcinoma according to age: a competing-risks regression analysis. , 2011, European urology.

[36]  S. Herrell,et al.  Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. , 2011, European urology.

[37]  R. Uzzo,et al.  Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  R. Uzzo,et al.  Adjuvant therapy for high-risk renal cell carcinoma patients , 2007, Current urology reports.

[39]  B. Hollenbeck,et al.  Five‐year survival after surgical treatment for kidney cancer , 2007, Cancer.

[40]  S. Joniau,et al.  Comparison between open partial and radical nephrectomy for renal tumours: perioperative outcome and health-related quality of life. , 2007, European urology.

[41]  M. Kattan,et al.  Primer: using decision analysis to improve clinical decision making in urology , 2006, Nature Clinical Practice Urology.

[42]  P. Ewings,et al.  The assessment of patient life‐expectancy: how accurate are urologists and oncologists? , 2005, BJU international.

[43]  N. Christakis,et al.  Complexities in prognostication in advanced cancer: "to help them live their lives the way they want to". , 2003, JAMA.

[44]  J. Habbema,et al.  Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. , 2001, Journal of clinical epidemiology.

[45]  N. Christakis,et al.  Extent and determinants of error in physicians' prognoses in terminally ill patients: prospective cohort study. , 2000, The Western journal of medicine.

[46]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[47]  Frank E. Harrell,et al.  Prediction models need appropriate internal, internal-external, and external validation. , 2016, Journal of clinical epidemiology.

[48]  F. Montorsi,et al.  A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma. , 2014, Urologic oncology.

[49]  Mark W. Ball,et al.  Survival after diagnosis of localized T1a kidney cancer: current population-based practice of surgery and nonsurgical management. , 2014, Urology.

[50]  Brenda R. Hemmelgarn,et al.  Notice , 2012, Kidney International Supplements.

[51]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[52]  R. Sylvester,et al.  A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. , 2011, European urology.

[53]  Douglas G Altman,et al.  Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines , 2009, BMC medical research methodology.